Ranbaxy looks good from an investment side: Shrikant Shetty
Shrikant Shetty, Head, Equity Advisory Unicon Investment Solutions, in a chat with ET Now, talks about Bharti and Ranbaxy.
By 
|
| We have got Bharti and RIL for inaction for specific reasons. Ranbaxy numbers are also expected later on this week. Are you expecting anything particular there?
In Bharti we are a bit cautious. I think from a trading perspective it can rally back to 295-300 levels but in general we think it should be range bound given this deal which has happened. Unless there is more clarity on the dealers on equity funding and what extent of dilution will happen for the stock. That is something which we need to see and post that one could take a more proper view on the stock.
In terms of Ranbaxy results should be good. One I think the currency factor also should favourable. There have been some negative news flows on the FDA front which I think if the management is able to address, the stock looks pretty good from an investment side.
In Bharti we are a bit cautious. I think from a trading perspective it can rally back to 295-300 levels but in general we think it should be range bound given this deal which has happened. Unless there is more clarity on the dealers on equity funding and what extent of dilution will happen for the stock. That is something which we need to see and post that one could take a more proper view on the stock.
In terms of Ranbaxy results should be good. One I think the currency factor also should favourable. There have been some negative news flows on the FDA front which I think if the management is able to address, the stock looks pretty good from an investment side.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
